2,3-diidro-5-metil-6-fenilimidazo<2,1-b>tiazolo | 75224-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,3-diidro-5-metil-6-fenilimidazo<2,1-b>tiazolo
• 英文别名: 2,3-diidro-5-metil-6-fenilimidazo[2,1-b]tiazolo；5-Methyl-6-phenyl-2,3-dihydroimidazo[2,1-b][1,3]thiazole
• CAS: 75224-70-3
• 化学式: C₁₂H₁₂N₂S
• 分子量: 216.307
• InChiKey: MLXHVWAJZZSKOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-diidro-5-metil-6-fenilimidazo<2,1-b>tiazolo 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 8.0h， 以22%的产率得到6-苯基-2,3-二氢咪唑[2,1-B] 噻唑-5-甲醛
  参考文献：
  名称：

  Andreani; Rambaldi; Bonazzi, Farmaco, Edizione Scientifica, 1980, vol. 35, # 7, p. 573 - 580

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-2-噻唑啉 、 2-溴苯丙酮 生成 2,3-diidro-5-metil-6-fenilimidazo<2,1-b>tiazolo
  参考文献：
  名称：

  Andreani; Rambaldi; Bonazzi, Farmaco, Edizione Scientifica, 1980, vol. 35, # 7, p. 573 - 580

  摘要：

  DOI：

文献信息

• BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Oshima Kunio

  公开号：US20130040941A1

  公开（公告）日：2013-02-14

  The present invention provides a novel benzodiazepine compound that blocks the I Kur current or the Kv1.5 channel potently and more selectively than other K + channels. The benzodiazepine compound of the invention is represented by General Formula (1) wherein R 1 , R 2 , R 3 , and R 4 are each independently hydrogen or lower alkyl; R 2 and R 3 may be linked to form lower alkylene; A 1 is lower alkylene optionally substituted with one or more hydroxy; and R 5 is group represented by wherein R 6 and R 7 are each independently hydrogen or organic group; X A and X B are each independently bond, lower alkylene, etc.

  本发明提供了一种新型苯二氮平化合物，能够有效地阻断IKur电流或Kv1.5通道，比其他K+通道更具选择性。本发明的苯二氮平化合物由通式（1）表示，其中R1、R2、R3和R4各自独立地为氢或低碳基；R2和R3可以连接形成低碳链；A1为低碳链，可选地取代一个或多个羟基；R5为由下式表示的基团：其中R6和R7各自独立地为氢或有机基团；XA和XB各自独立地为键，低碳链等。
• INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3885343A1

  公开（公告）日：2021-09-29

  The present disclosure provides compounds of Formula (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

  本公开提供了式（II）化合物。 本文所述化合物是组蛋白甲基转移酶（如泽斯特同源增强子 1 (EZH1) 和泽斯特同源增强子 2 (EZH2)）的抑制剂，可用于治疗和/或预防多种疾病（如增殖性疾病）。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。本公开还提供了鉴定EZH1和/或EZH2抑制剂的方法。
• DIAZEPANE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145023A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
• DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145013A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
• US8338406B2
  申请人：——

  公开号：US8338406B2

  公开（公告）日：2012-12-25